ArticleInternational journal of clinical and experimental pathology2018
Downregulation of miR-181a alleviates renal fibrosis in diabetic nephropathy mice.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Unraveling the role of MiR-181 in skin fibrosis pathogenesis by targeting NUDT21.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggests that microRNAs are important regulators in the pathology of diabetes and its relevant renal injures. Little is known about the role of miR-181a in development of diabetic nephropathy. The aim of our present study was to investigate levels of miR-181a in diabetic nephropathy and explore its underlying mechanism. In the present study, Db/db and db/m mice were randomized into groups with 12 mice in each: db/m group, db/db group, and antagomiR-181a-treated db/db group. Changes in renal cortical sections were studied by histopathology. Mouse mesangial cells transfected with miR-mimic or miR-inhibitor and cell growth was measured using MTT assay. Levels of miR-181a expression were detected using qRT-PCR under different conditions. Indexes were measured using qRT-PCR and Western blot. Our results show that downregulation of miR-181a could alleviate pathological changes of diabetic nephropathy in mice. miR-181a expression was significantly upregulated in mouse mesaginal cells
Indexed as
Identifiers
31949789PMC6962790W3026414650What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.